Notey Biological disclosure 2022 semi -annual report achieved revenue of 268 million yuan

On August 29, Norita Biological (code: 688076.SH) released the 2022 semi -annual performance report.

From January 1, 2022-June 30, 2022, the company realized operating income of 268 million yuan, a year-on-year decrease of 13.17%, and net profit was 34.8336 million yuan, a year-on-year decrease of 32.25%, and the basic earnings per share were 0.16 yuan.

The company's industry serves medical care.

During the company's reporting period, the total assets at the end of the period were 2.305 billion yuan, the operating profit was 26.3587 million yuan, the accounts receivable were 175 million yuan, and the net cash flow generated by operating activities was -14.608 million yuan.The cash is 227 million yuan.

Notey Biological, the company's full name is Jiangsu Nuotai Ao Nuo Nuo Biopharmaceutical Co., Ltd., was established on April 03, 2009. The current general manager Tong Ziquan, the main business is polypeptide drugs and small molecular chemical drugs for independent development, customized research and development and productionEssence

- END -